This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pruimboom-Brees, I. Articles by Francone, O. L. Search for Related Content PubMed PubMed Citation Articles by Pruimboom-Brees, I. Articles by Francone, O. L.

(American Journal of Pathology. 2006;169:750-760.)
© 2006 American Society for Investigative Pathology
DOI: 10.2353/ajpath.2006.051110

A Critical Role for Peroxisomal Proliferator-Activated Receptor- Nuclear Receptors in the Development of Cardiomyocyte Degeneration and Necrosis

From Pfizer Global Research and Development, Groton, Connecticut

Peroxisomal proliferator-activated receptor (PPAR)- is a ligand-activated transcriptional factor that regulates genes involved in lipid metabolism and energy homeostasis. PPAR- activators, including fibrates, have been used to treat dyslipidemia for several decades. In contrast to their known effects on lipids, the pharmacological consequences of PPAR- activation on cardiac metabolism and function are not well understood. Therefore, we evaluated the role that PPAR- receptors play in the heart. Our studies demonstrate that activation of PPAR- receptors using a selective PPAR- ligand results in cardiomyocyte necrosis in mice. Studies in PPAR--deficient mice demonstrated that cardiomyocyte necrosis is a consequence of the activation of PPAR- receptors. Cardiac fatty acyl-CoA oxidase mRNA levels increased at doses in which cardiac damage was observed and temporally preceded cardiomyocyte degeneration, suggesting that peroxisomal ß-oxidation correlates with the appearance of microscopic injury and cardiac injury biomarkers. Increased myocardial oxidative stress was evident in mice treated with the PPAR- agonists coinciding with increased peroxisomal biomarkers of fatty acid oxidation. These findings suggest that activation of PPAR- leads to increased cardiac fatty acid oxidation and subsequent accumulation of oxidative stress intermediates resulting in cardiomyocyte necrosis.

This article has been cited by other articles:

				M. Ueno, J. Suzuki, Y. Zenimaru, S. Takahashi, T. Koizumi, S. Noriki, O. Yamaguchi, K. Otsu, W.-J. Shen, F. B. Kraemer, et al. Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E1109 - E1118. [Abstract] [Full Text] [PDF]

				P. J.H. Smeets, B. E.J. Teunissen, P. H.M. Willemsen, F. A. van Nieuwenhoven, A. E. Brouns, B. J.A. Janssen, J. P.M. Cleutjens, B. Staels, G. J. van der Vusse, and M. van Bilsen Cardiac hypertrophy is enhanced in PPAR{alpha}-/- mice in response to chronic pressure overload Cardiovasc Res, April 1, 2008; 78(1): 79 - 89. [Abstract] [Full Text] [PDF]

				F. Sharifpanah, M. Wartenberg, M. Hannig, H.-M. Piper, and H. Sauer Peroxisome Proliferator-Activated Receptor {alpha} Agonists Enhance Cardiomyogenesis of Mouse ES Cells by Utilization of a Reactive Oxygen Species-Dependent Mechanism Stem Cells, January 1, 2008; 26(1): 64 - 71. [Abstract] [Full Text] [PDF]

				B. N. Finck and D. P. Kelly Peroxisome Proliferator-Activated Receptor {gamma} Coactivator-1 (PGC-1) Regulatory Cascade in Cardiac Physiology and Disease Circulation, May 15, 2007; 115(19): 2540 - 2548. [Full Text] [PDF]